In obese patients with T2DM, the plasma DPP‐4 activity is increased resulting in reduced incretin effect and thereby decreasing the efficacy of DPP‐4 inhibitor therapy.18, 19 In addition, bariatric surgery aimed at weight loss in individuals with T2DM shown to alter GLP‐1 dynamics resulting in improved secretory response to nutrient intake. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.